Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors.
Borad M, Ramanathan R, Bessudo A, LoRusso P, Shepard H, Maneval D, Jiang P, Zhu J, Frost G, Infante J. Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. Journal Of Clinical Oncology 2012, 30: 2579-2579. DOI: 10.1200/jco.2012.30.15_suppl.2579.Peer-Reviewed Original ResearchMusculoskeletal eventsSolid tumorsFDG-PETDCE-MRITumor biopsiesTumor perfusionInterstitial fluid pressureOngoing phase 1 studiesTreatment-refractory solid tumorsWeekly dosing scheduleDose limiting toxicitiesPhase 1 studyWeeks of dosingEfficacy of chemotherapyTerminal half lifeFDG-PET imagesOral dexamethasoneTumor hyaluronanCytotoxic chemotherapyMost patientsDosing schedulesLimiting toxicitiesPoor prognosisSystemic exposureHA depletion